schliessen

Filtern

 

Bibliotheken

Cost-effectiveness analysis of the addition of bevacizumab to chemotherapy as induction and maintenance therapy for metastatic non-squamous non-small-cell lung cancer.

BACKGROUNDThe BEYOND trial found that the addition of bevacizumab (B) to paclitaxel-carboplatin (PC) chemotherapy provided a significant clinical benefit to Chinese patients with metastatic non-squamous non-small-cell lung cancer (NSCLC). This study aimed...

Journal Title: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico March 2018, Vol.20(3), pp.286-293
Main Author: Zheng, H
Other Authors: Xie, L , Zhan, M , Wen, F , Xu, T , Li, Q
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: E-ISSN: 1699-3055 ; DOI: 10.1007/s12094-017-1715-1
Link: http://search.proquest.com/docview/1927307465/?pq-origsite=primo
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest1927307465
title: Cost-effectiveness analysis of the addition of bevacizumab to chemotherapy as induction and maintenance therapy for metastatic non-squamous non-small-cell lung cancer.
format: Article
creator:
  • Zheng, H
  • Xie, L
  • Zhan, M
  • Wen, F
  • Xu, T
  • Li, Q
subjects:
  • Adenocarcinoma–Drug Therapy
  • Antineoplastic Agents, Immunological–Administration & Dosage
  • Antineoplastic Combined Chemotherapy Protocols–Economics
  • Bevacizumab–Administration & Dosage
  • Carboplatin–Administration & Dosage
  • Carcinoma, Large Cell–Economics
  • Carcinoma, Non-Small-Cell Lung–Administration & Dosage
  • China–Drug Therapy
  • Cost-Benefit Analysis–Drug Therapy
  • Humans–Economics
  • Induction Chemotherapy–Methods
  • Lung Neoplasms–Drug Therapy
  • Maintenance Chemotherapy–Economics
  • Paclitaxel–Methods
  • Paclitaxel–Administration & Dosage
  • Antineoplastic Agents, Immunological
  • Bevacizumab
  • Carboplatin
  • Paclitaxel
  • Cost-Effectiveness
  • Induction and Maintenance Therapy
  • Metastatic Non-Small-Cell Lung Cancer
ispartof: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, March 2018, Vol.20(3), pp.286-293
description: BACKGROUNDThe BEYOND trial found that the addition of bevacizumab (B) to paclitaxel-carboplatin (PC) chemotherapy provided a significant clinical benefit to Chinese patients with metastatic non-squamous non-small-cell lung cancer (NSCLC). This study aimed...
language: eng
source:
identifier: E-ISSN: 1699-3055 ; DOI: 10.1007/s12094-017-1715-1
fulltext: fulltext
issn:
  • 16993055
  • 1699-3055
url: Link


@attributes
ID566673718
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid1927307465
sourceidproquest
recordidTN_proquest1927307465
sourcesystemPC
pqid1927307465
display
typearticle
titleCost-effectiveness analysis of the addition of bevacizumab to chemotherapy as induction and maintenance therapy for metastatic non-squamous non-small-cell lung cancer.
creatorZheng, H ; Xie, L ; Zhan, M ; Wen, F ; Xu, T ; Li, Q
contributorZheng, H (correspondence author) ; Zheng, H (record owner)
ispartofClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, March 2018, Vol.20(3), pp.286-293
identifierE-ISSN: 1699-3055 ; DOI: 10.1007/s12094-017-1715-1
subjectAdenocarcinoma–Drug Therapy ; Antineoplastic Agents, Immunological–Administration & Dosage ; Antineoplastic Combined Chemotherapy Protocols–Economics ; Bevacizumab–Administration & Dosage ; Carboplatin–Administration & Dosage ; Carcinoma, Large Cell–Economics ; Carcinoma, Non-Small-Cell Lung–Administration & Dosage ; China–Drug Therapy ; Cost-Benefit Analysis–Drug Therapy ; Humans–Economics ; Induction Chemotherapy–Methods ; Lung Neoplasms–Drug Therapy ; Maintenance Chemotherapy–Economics ; Paclitaxel–Methods ; Paclitaxel–Administration & Dosage ; Antineoplastic Agents, Immunological ; Bevacizumab ; Carboplatin ; Paclitaxel ; Cost-Effectiveness ; Induction and Maintenance Therapy ; Metastatic Non-Small-Cell Lung Cancer
descriptionBACKGROUNDThe BEYOND trial found that the addition of bevacizumab (B) to paclitaxel-carboplatin (PC) chemotherapy provided a significant clinical benefit to Chinese patients with metastatic non-squamous non-small-cell lung cancer (NSCLC). This study aimed...
languageeng
source
version4
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://search.proquest.com/docview/1927307465/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontrib
0Zheng, H
1Xie, L
2Zhan, M
3Wen, F
4Xu, T
5Li, Q
titleCost-effectiveness analysis of the addition of bevacizumab to chemotherapy as induction and maintenance therapy for metastatic non-squamous non-small-cell lung cancer.
descriptionBACKGROUNDThe BEYOND trial found that the addition of bevacizumab (B) to paclitaxel-carboplatin (PC) chemotherapy provided a significant clinical benefit to Chinese patients with metastatic non-squamous non-small-cell lung cancer (NSCLC). This study aimed...
subject
0Adenocarcinoma–Drug Therapy
1Antineoplastic Agents, Immunological–Administration & Dosage
2Antineoplastic Combined Chemotherapy Protocols–Economics
3Bevacizumab–Administration & Dosage
4Carboplatin–Administration & Dosage
5Carcinoma, Large Cell–Economics...
6Cost-effectiveness
7Induction and maintenance therapy
8Metastatic non-small-cell lung cancer
general
0English
110.1007/s12094-017-1715-1
2MEDLINE (ProQuest)
3ProQuest Biological Science Collection
4ProQuest Natural Science Collection
5ProQuest SciTech Collection
6Biological Science Database
7Natural Science Collection
8SciTech Premium Collection
9Health Research Premium Collection
10Health Research Premium Collection (Alumni edition)
11Biological Science Index (ProQuest)
sourceidproquest
recordidproquest1927307465
issn
016993055
11699-3055
rsrctypearticle
creationdate2018
addtitleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
searchscope
01007527
11007944
21009130
310000004
410000038
510000050
610000120
710000159
810000238
910000253
1010000260
1110000270
1210000271
1310000302
1410000350
15proquest
scope
01007527
11007944
21009130
310000004
410000038
510000050
610000120
710000159
810000238
910000253
1010000260
1110000270
1210000271
1310000302
1410000350
15proquest
lsr43
01007527false
11007944false
21009130false
310000004false
410000038false
510000050false
610000120false
710000159false
810000238false
910000253false
1010000260false
1110000270false
1210000271false
1310000302false
1410000350false
contributorZheng, H
startdate20180301
enddate20180301
citationpf 286 pt 293 vol 20 issue 3
lsr30VSR-Enriched:[issn, pqid, orcidid, date]
sort
titleCost-effectiveness analysis of the addition of bevacizumab to chemotherapy as induction and maintenance therapy for metastatic non-squamous non-small-cell lung cancer.
authorZheng, H ; Xie, L ; Zhan, M ; Wen, F ; Xu, T ; Li, Q
creationdate20180301
lso0120180301
facets
frbrgroupid7102098254805071809
frbrtype5
newrecords20181218
languageeng
creationdate2018
topic
0Adenocarcinoma–Drug Therapy
1Antineoplastic Agents, Immunological–Administration & Dosage
2Antineoplastic Combined Chemotherapy Protocols–Economics
3Bevacizumab–Administration & Dosage
4Carboplatin–Administration & Dosage
5Carcinoma, Large Cell–Economics...
collection
0MEDLINE (ProQuest)
1ProQuest Biological Science Collection
2ProQuest Natural Science Collection
3ProQuest SciTech Collection
4Biological Science Database
5Natural Science Collection
6SciTech Premium Collection
7Health Research Premium Collection
8Health Research Premium Collection (Alumni edition)
9Biological Science Index (ProQuest)
prefilterarticles
rsrctypearticles
creatorcontrib
0Zheng, H
1Xie, L
2Zhan, M
3Wen, F
4Xu, T
5Li, Q
jtitleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Zheng
1Xie
2Zhan
3Wen
4Xu
5Li
aufirst
0H
1L
2M
3F
4T
5Q
au
0Zheng, H
1Xie, L
2Zhan, M
3Wen, F
4Xu, T
5Li, Q
addauZheng, H
atitleCost-effectiveness analysis of the addition of bevacizumab to chemotherapy as induction and maintenance therapy for metastatic non-squamous non-small-cell lung cancer.
jtitleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
risdate20180301
volume20
issue3
spage286
epage293
pages286-293
eissn1699-3055
formatjournal
genrearticle
ristypeJOUR
abstractBACKGROUNDThe BEYOND trial found that the addition of bevacizumab (B) to paclitaxel-carboplatin (PC) chemotherapy provided a significant clinical benefit to Chinese patients with metastatic non-squamous non-small-cell lung cancer (NSCLC). This study aimed...
doi10.1007/s12094-017-1715-1
urlhttp://search.proquest.com/docview/1927307465/
orcididhttp://orcid.org/0000-0002-4239-4170
issn1699048X
date2018-03